Dr Cid presents phase 2 trial of anti-GM-CSF agent mavrilimumab in combination with steroids in GCA. 70 patients. Sustained remission at week 26 in 83.2% of mavrilimumab vs 49.9% of placebo p=0.0038. @rheumnow @DrPujaMehta1 #ACR20 Abstr#L06 #ACRbest https://t.co/MTuH0sAuWt